百濟神州(06160.HK)藥物獲英國衛生研究所推薦用於治療華氏巨球蛋白血症患者
百濟神州(06160.HK)公布,英國衛生技術評估機構英國國家衛生與臨床優化研究所(NICE)已發佈最終評估檔,推薦百悅澤(R)(澤布替尼)用於治療既往接受過至少一種治療,且適用於苯達莫司汀-利妥昔單抗聯合用藥(BR)的華氏巨球蛋白血症(WM)成人患者。
NICE的決定標誌著百悅澤(R)成為英格蘭和威爾士地區首個也是唯一一個被推薦用於治療WM的常規藥物。WM是一種罕見的B細胞淋巴瘤,僅佔非霍奇金淋巴瘤患者群體的2%。英國目前約有4,000名WM患者。
臨床證據顯示,與標準療法相比,接受百悅澤(R)治療的WM患者生存期更長,且生活品質更高。NICE認為百悅澤(R)具有成本優勢,其每個品質調整生命年(QALY)的治療費用最低僅為2萬至3萬英鎊。
百悅澤(R)(澤布替尼)是一款由百濟神州科學家自主研發的布魯頓氏酪氨酸激(酉每)(BTK)小分子抑制劑,目前正在全球進行廣泛的臨床試驗項目,作為單藥和與其他療法進行聯合用藥治療多種B細胞惡性腫瘤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.